<?xml version="1.0" ?>
<document id="cafa25b00fd0b65e7d337fd03a204be2acb3243f">
  <chunk id="cafa25b00fd0b65e7d337fd03a204be2acb3243f.c0" text="Pre-Clinical and Clinical Efficiency of Complexes of Oligoribonucleotides with D-Mannitol against Respiratory Viruses"/>
  <chunk id="cafa25b00fd0b65e7d337fd03a204be2acb3243f.c1" text="Oligoribonucleotides-D-mannitol (ORNs-D-M) complexes possess antiviral, anti-inflammatory, and immunomodulatory actions. The aim of the present study was to evaluated an antiviral effect of ORNs-D-M against parainfluenza virus type 3 (PIV3); influenza CA709, PR834; avian influenza virus H5N2 (AIV) in vitro by a TCID 50 ; hemadsorption and neuraminidase activity assays; and clinical efficiency of ORNs-D-M in patients with acute respiratory infections (ARIs) of various etiologies by PCR assay and AmpliSens test systems. It was observed that ORNs-D-M have an antiviral activity against the influenza CA709, PR834, PIV3, and AIV in vitro. The injectable dosage form of ORNs-D-M was shown to have a stronger antiviral effect compared to capsule form. It was also detected that the injectable form of ORNs-D-M significantly reduced the neuraminidase activity of influenza PR834. A complex treatment of patients with ORNs-D-M had a positive effect on the course of the disease, it accelerated patients' recovery. Treatment with ORNs-D-M caused eradication of adeno-and influenza viruses in patients with ARI. This drug contributed to significant decrease in duration of febrile period and cough. Comprehensive treatment with ORNs-D-M improved the disease clinical findings significantly. Collectively, these results suggested that ORNs-D-M may be used at co-infection with influenza and other respiratory viruses as a medical antiviral drug.">
    <entity charOffset="341-363" id="cafa25b00fd0b65e7d337fd03a204be2acb3243f.c1.e0" ontology_id="GO_0004308" text="neuraminidase activity" type="gene_function"/>
    <entity charOffset="425-430" id="cafa25b00fd0b65e7d337fd03a204be2acb3243f.c1.e1" ontology_id="HP_0011009" text="acute" type="phenotype"/>
    <entity charOffset="431-453" id="cafa25b00fd0b65e7d337fd03a204be2acb3243f.c1.e2" ontology_id="HP_0011947" text="respiratory infections" type="phenotype"/>
    <entity charOffset="738-745" id="cafa25b00fd0b65e7d337fd03a204be2acb3243f.c1.e3" ontology_id="GO_0042603" text="capsule" type="gene_function"/>
    <entity charOffset="836-858" id="cafa25b00fd0b65e7d337fd03a204be2acb3243f.c1.e4" ontology_id="GO_0004308" text="neuraminidase activity" type="gene_function"/>
    <pair e1="cafa25b00fd0b65e7d337fd03a204be2acb3243f.c1.e0" e2="cafa25b00fd0b65e7d337fd03a204be2acb3243f.c1.e1" id="cafa25b00fd0b65e7d337fd03a204be2acb3243f.c1.p0" relation="true"/>
    <pair e1="cafa25b00fd0b65e7d337fd03a204be2acb3243f.c1.e0" e2="cafa25b00fd0b65e7d337fd03a204be2acb3243f.c1.e2" id="cafa25b00fd0b65e7d337fd03a204be2acb3243f.c1.p1" relation="true"/>
    <pair e1="cafa25b00fd0b65e7d337fd03a204be2acb3243f.c1.e1" e2="cafa25b00fd0b65e7d337fd03a204be2acb3243f.c1.e3" id="cafa25b00fd0b65e7d337fd03a204be2acb3243f.c1.p2" relation="true"/>
    <pair e1="cafa25b00fd0b65e7d337fd03a204be2acb3243f.c1.e1" e2="cafa25b00fd0b65e7d337fd03a204be2acb3243f.c1.e4" id="cafa25b00fd0b65e7d337fd03a204be2acb3243f.c1.p3" relation="true"/>
    <pair e1="cafa25b00fd0b65e7d337fd03a204be2acb3243f.c1.e2" e2="cafa25b00fd0b65e7d337fd03a204be2acb3243f.c1.e3" id="cafa25b00fd0b65e7d337fd03a204be2acb3243f.c1.p4" relation="true"/>
    <pair e1="cafa25b00fd0b65e7d337fd03a204be2acb3243f.c1.e2" e2="cafa25b00fd0b65e7d337fd03a204be2acb3243f.c1.e4" id="cafa25b00fd0b65e7d337fd03a204be2acb3243f.c1.p5" relation="true"/>
  </chunk>
</document>
